CsA CE was well-tolerated and effective in improving corneal damage and ocular surface inflammation and confirmed the positive benefit-risk ratio of this new formulation of CsA for the treatment of severe keratitis in DED.
Purpose: Vernal keratoconjunctivitis (VKC) is a chronic, allergic, and potentially severe ocular disease affecting children and adolescents that can lead to impaired quality of life (QoL) and loss of vision. This study evaluated the efficacy and safety of an investigational therapy for severe VKC, cyclosporine A (CsA) cationic emulsion (CE), an oil-in-water emulsion with increased bioavailability versus conventional CsA formulations.Design: The VErnal KeratoconjunctiviTIs Study (VEKTIS) is a phase 3, multicenter, double-masked, vehiclecontrolled trial.Participants: Pediatric patients (4 to younger than 18 years) with active severe VKC (grade of 3 or 4 on the Bonini severity scale) and severe keratitis (corneal fluorescein staining [CFS] score of 4 or 5 on the modified Oxford scale).Methods: One hundred sixty-nine patients were randomized to CsA CE 0.1% (1 mg/ml) eye drops 4 times daily (high dose), CsA CE twice daily (low dose) plus vehicle twice daily, or vehicle 4 times daily for 4 months.Main Outcome Measures: The primary end point was a mean composite score that reflected CFS, rescue medication use (dexamethasone 0.1% 4 times daily), and corneal ulceration over the 4 months.Results: Differences in least-squares means versus vehicle for the primary end point were statistically significant for both the high-dose (0.76; P ¼ 0.007) and the low-dose (0.67; P ¼ 0.010) groups, with treatment effect mainly driven by CFS score. Significant differences were found between both active treatment groups and vehicle for use of rescue medication. Vernal keratoconjunctivitis symptoms and patient QoL (assessed by visual analog scale and the Quality of Life in Children with Vernal Keratoconjunctivitis questionnaire) improved in all 3 groups, with significant improvements for high-dose CsA CE versus vehicle.Conclusions: The efficacy of high-dose CsA CE in improving keratitis, symptoms, and QoL for those with severe VKC was demonstrated in these study patients. In addition, in this study cohort, CsA CE was well tolerated.
Purpose
The SICCANOVE study aimed to compare the efficacy and safety of 0.1%
cyclosporine A cationic emulsion (CsA CE) versus vehicle in patients with
moderate to severe dry eye disease (DED).
Methods
In this multicenter, double-masked, parallel-group, controlled study,
patients were randomized (1:1) to receive CsA CE (Ikervis
®
) or
vehicle for 6 months. The co-primary efficacy endpoints at month 6 were mean
change from baseline in corneal fluorescein staining (CFS; modified Oxford
scale) and in global ocular discomfort (visual analogue scale [VAS]).
Results
The mean change in CFS from baseline to month 6 (CsA CE: n = 241; vehicle: n
= 248) was significantly greater with CsA CE than with vehicle (-1.05 ± 0.98
and -0.82 ± 0.94, respectively; p = 0.009). Ocular discomfort improved
similarly in both groups; however, the percentage of patients with ≥25%
improvement in VAS was significantly higher with CsA CE (50.2%) than with
vehicle (41.9%; p = 0.048). In a post hoc analysis of patients with severe
ocular surface damage (CFS score 4) at baseline (CsA CE: n = 43; vehicle: n
= 42), the percentage of patients with improvements of ≥2 grades in CFS
score and ≥30% in Ocular Surface Disease Index score was significantly
greater with CsA CE (p = 0.003). Treatment compliance and ocular
tolerability were satisfactory and as expected for CsA use.
Conclusion
Cyclosporine A CE was well-tolerated and effectively improved signs and
symptoms in patients with moderate to severe DED over 6 months, especially
in patients with severe disease, who are at risk of irreversible corneal
damage.
CE was similar to HS with regards to safety and efficacy for objective signs but was superior to HS in improving DED symptoms in patients with moderate to severe DED.
Components of the ocular surface synergistically contribute to maintaining and protecting a smooth refractive layer to facilitate the optimal transmission of light. At the air–water interface, the tear film lipid layer (TFLL), a mixture of lipids and proteins, plays a key role in tear surface tension and is important for the physiological hydration of the ocular surface and for ocular homeostasis. Alterations in tear fluid rheology, differences in lipid composition, or downregulation of specific tear proteins are found in most types of ocular surface disease, including dry eye disease (DED). Artificial tears have long been a first line of treatment in DED and aim to replace or supplement tears. More recently, lipid-containing eye drops have been developed to more closely mimic the combination of aqueous and lipid layers of the TFLL. Over the last 2 decades, our understanding of the nature and importance of lipids in the tear film in health and disease has increased substantially. The aim of this article is to provide a brief overview of our current understanding of tear film properties and review the effectiveness of lipid-based products in the treatment of DED. Liposome lid sprays, emulsion eye drops, and other lipid-containing formulations are discussed.
In this 12-month study, once-daily CsA CE was well-tolerated and showed reductions in ocular surface inflammation and improvements in signs/symptoms in DED patients with severe keratitis.
background/aim To assess the treatment effect of 0.1% ciclosporin A cationic emulsion (CsA CE) versus vehicle on signs/symptoms of dry eye disease (DED) in various subgroups (moderate-to-severe DED/severe DED/ Sjögren's syndrome (SS)/SS with severe DED). Methods Pooled data were analysed from two similar phase III studies: SICCANOVE (moderate-to-severe DED) and SANSIKA (severe DED with severe keratitis). In both studies, patients aged ≥18 years received CsA CE 0.1%
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.